[go: up one dir, main page]

GT200500387A - Formulaciones inyectables o administrables por via oral de derivados de azetidina - Google Patents

Formulaciones inyectables o administrables por via oral de derivados de azetidina

Info

Publication number
GT200500387A
GT200500387A GT200500387A GT200500387A GT200500387A GT 200500387 A GT200500387 A GT 200500387A GT 200500387 A GT200500387 A GT 200500387A GT 200500387 A GT200500387 A GT 200500387A GT 200500387 A GT200500387 A GT 200500387A
Authority
GT
Guatemala
Prior art keywords
injectable
oral route
derivatives
azetidine
administrable formulations
Prior art date
Application number
GT200500387A
Other languages
English (en)
Inventor
Maria-Teresa Peracchia
Gilbert Gaudel
Sophie Cote
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200500387A publication Critical patent/GT200500387A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A FORMULACIONES BINARIAS O TERNARIAS INYECTABLES O ADMINISTRABLES POR VIA ORAL DE COMPUESTOS DERIVADOS DE N-(1-(BIS-(4-CLOROFENIL)-METIL-AZETIDIN-3-IL)-N-(3,5-DIFLUOROFENIL)-METILSULFONAMIDA CON POLISORBATO 80 O SOLUTOL HS 15 COMO EXCIPIENTES. LOS DERIVADOS UTILIZADOS EN LAS COMPOSICIONES FARMACEUTICAS SEGUN LA INVENCION PUEDEN DESIGNARSE POR LAS FORMULAS GENERALES (IA) O (IB).
GT200500387A 2004-12-27 2005-12-22 Formulaciones inyectables o administrables por via oral de derivados de azetidina GT200500387A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0413937A FR2879932B1 (fr) 2004-12-27 2004-12-27 Formulations injectable ou administrable par voie orale de derives d'azetidine

Publications (1)

Publication Number Publication Date
GT200500387A true GT200500387A (es) 2006-07-03

Family

ID=34952941

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500387A GT200500387A (es) 2004-12-27 2005-12-22 Formulaciones inyectables o administrables por via oral de derivados de azetidina

Country Status (20)

Country Link
US (2) US20070244085A1 (es)
EP (1) EP1835906A1 (es)
JP (1) JP2008525390A (es)
KR (1) KR20070092970A (es)
CN (1) CN101090719A (es)
AR (1) AR052181A1 (es)
AU (1) AU2005321112A1 (es)
BR (1) BRPI0519271A2 (es)
CA (1) CA2586895A1 (es)
FR (1) FR2879932B1 (es)
GT (1) GT200500387A (es)
IL (1) IL183483A0 (es)
MX (1) MX2007006926A (es)
PA (1) PA8658201A1 (es)
PE (1) PE20060743A1 (es)
RU (1) RU2007128812A (es)
SV (1) SV2006002355A (es)
TW (1) TW200635581A (es)
UY (1) UY29318A1 (es)
WO (1) WO2006070129A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2463565A (en) * 2008-09-12 2010-03-24 Critical Pharmaceuticals Ltd Improvements in the absorption of therapeutic agents across mucosal membranes or the skin
FR2948568B1 (fr) * 2009-07-30 2012-08-24 Sanofi Aventis Formulation pharmaceutique
CA2982162C (en) * 2015-04-10 2023-10-10 Bioresponse, L.L.C. Self-emulsifying formulations of dim-related indoles
WO2020257336A1 (en) 2019-06-18 2020-12-24 Opiant Pharmaceuticals, Inc. Compositions and methods for treating cannabinoid hyperemesis syndrome with a cannabinoid receptor antagonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0177158B1 (ko) * 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
US5516770A (en) * 1993-09-30 1996-05-14 American Home Products Corporation Rapamycin formulation for IV injection
JP2003500368A (ja) * 1999-05-24 2003-01-07 ソーナス ファーマシューティカルス，インコーポレイテッド 溶解度が不十分な薬剤のためのエマルジョンビヒクル
FR2833842B1 (fr) * 2001-12-21 2004-02-13 Aventis Pharma Sa Compositions pharmaceutiques a base de derives d'azetidine

Also Published As

Publication number Publication date
CA2586895A1 (fr) 2006-07-06
EP1835906A1 (fr) 2007-09-26
TW200635581A (en) 2006-10-16
MX2007006926A (es) 2007-08-06
PA8658201A1 (es) 2006-08-03
KR20070092970A (ko) 2007-09-14
WO2006070129A1 (fr) 2006-07-06
RU2007128812A (ru) 2009-02-10
FR2879932B1 (fr) 2007-03-23
US20100022501A1 (en) 2010-01-28
AR052181A1 (es) 2007-03-07
CN101090719A (zh) 2007-12-19
PE20060743A1 (es) 2006-09-13
AU2005321112A1 (en) 2006-07-06
IL183483A0 (en) 2007-09-20
UY29318A1 (es) 2006-07-31
FR2879932A1 (fr) 2006-06-30
SV2006002355A (es) 2006-06-28
BRPI0519271A2 (pt) 2009-01-06
US20070244085A1 (en) 2007-10-18
JP2008525390A (ja) 2008-07-17

Similar Documents

Publication Publication Date Title
CY1118360T1 (el) Παρατεταμενης διαρκειας τοπικη αναισθητικη συνθεση η οποια περιεχει saib
ECSP088549A (es) Nuevos derivados de pirrol fusionado
NO20081724L (no) Stabil farmasoytisk sammensetning omfattende et pyrimidin-sulfamid
CO5590918A2 (es) Formulaciones
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
EA200702498A1 (ru) N-(пиридин-2-ил)сульфонамидные производные
PA8591701A1 (es) Derivados de pirrolopirimidina
ECSP088082A (es) Derivados de piridazina
ECSP088412A (es) Derivados de pirazina como moduladores de canal de sodio en el tratamiento del dolor
DK1915150T3 (da) Anvendelse af thienopyridinonderivater som AMPK-aktivatorer og farmaceutiske sammensætninger
EA200702198A1 (ru) Фармацевтические составы
ECSP088677A (es) Piperazinas y piperidinas como potenciadores 157 del mglur5
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
DE602005027540D1 (de) Feste formulierungen von ospemifen
BR112022007207A2 (pt) Composição farmacêutica que compreende selexipag
NO20054787D0 (no) Indenderivater som farmasotiske midler
EA200702253A1 (ru) Фармацевтическая композиция
ATE495159T1 (de) Diaminocyclohexan- und diaminocyclopentanderivate
DK1814848T3 (da) 2,3,4-substitueret-cyclopentanoner som terapeutiske midler
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
UY29134A1 (es) Sulfonamidas sustituidas por derivados de bencimidazol, composiciones que la contienen, procedimiento de preparacion y aplicaciones
GT200500387A (es) Formulaciones inyectables o administrables por via oral de derivados de azetidina
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
NO20063293L (no) Farmasoytiske forbindelser
NO20075766L (no) Aminoalkyl-amidometyl-substituerte 2-(4-sulfonylamino)-3-hydroksy-3,4-dihydro-2H-kromen-6-yl-derivater og deres anvendelse som kaliumkanalblokkere